title: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
abstract: For many cancer patients, removal of primary tumor is curative; however, if metastatic lesions exist and are not responsive to treatment, survival is limited. Although immunotherapy is actively being tested in animal models against primary tumors and experimental metastases (i.v. induced), very few studies have examined immunotherapy of spontaneous, established metastatic disease. The shortage of such studies can be attributed to the paucity of adequate animal models and to the concern that multiple metastatic lesions may be more resistant to immunotherapy than a localized primary tumor. Here, we use the BALB/c-derived mouse mammary carcinoma, 4T1, and show that this tumor very closely models human breast cancer in its immunogenicity, metastatic properties, and growth characteristics. Therapy studies demonstrate that treatment of mice with established primary and metastatic disease with MHC class II and B7.1-transfected tumor cells reduces or eliminates established spontaneous metastases but has no impact on primary tumor growth. These studies indicate that cell-based vaccines targeting the activation of CD4+ and CD8+ T cells may be effective agents for the treatment of malignancies, such as breast cancer, where the primary tumor is curable by conventional methods, but metastatic lesions remain refractile to current treatment modalities.
authors.affiliation: Department of Biological Sciences, University of Maryland Baltimore County, Baltimore 21250, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Pulaski
authors.forename: S
authors.initials: S
authors.lastname: Ostrand-Rosenberg
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002455:Cell Division / Q000502:physiology; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology*; D016233:Immunotherapy, Active; D008325:Mammary Neoplasms, Experimental / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology; D013866:Thioguanine / Q000494:pharmacology; D014162:Transfection
chemical_list: D000964:Antimetabolites, Antineoplastic; D018122:B7-1 Antigen; D019496:Cancer Vaccines; D000949:Histocompatibility Antigens Class II; D013866:Thioguanine